MEDA Pharma

This sponsor has funded 6 studies across 9 countries.

PAS funded by this sponsor.
EU PAS ID Status RMP requirement Title Protocol uploaded Results uploaded
4414 Finalised Not included in RMP Profile of patients prescribed Dymista® (azelastine hydrochloride/ fluticasone propionate) nasal spray for allergic rhinitis in the UK No No
11134 Finalised EU RMP category 1 Retrospective Chart Review to Evaluate the Effectiveness of the Risk Minimization Measures for the Use of Flupirtine 100 mg Immediate-Release Capsules... No Yes
12171 Ongoing EU RMP category 1 Retrospective Cohort Study on the Risk of Venous Thromboembolism with the use of combined oral contraceptives containing Chlormadinone... No No
12177 Finalised EU RMP category 1 Drug Utilization Study to Characterize the Prescribing Practice of Flupirtine-containing Medicinal Products during Typical Clinical Use and to Assess... No No
22774 Finalised Not included in RMP Observational study on persistent allergic rhinitis patients to evaluate effectiveness of Dymista® nasal spray in daily practice No No
23075 Finalised Not included in RMP Observational study to evaluate the actual use of Dymista® nasal spray in different allergic rhinitis patient phenotypes No No

PAS by Risk Management Plan (RMP) requirement

MEDA Pharma

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.